News & Media
Stay up to date with the latest press releases, media coverage, and company updates from Vyome Holdings.
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Feb 24, 2026
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Feb 18, 2026
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Feb 11, 2026
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Feb 2, 2026
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Jan 27, 2026
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Dec 22, 2025
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Dec 8, 2025
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Nov 25, 2025
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Nov 18, 2025
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
Sep 17, 2025
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
Sep 9, 2025
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW)
Sep 4, 2025
